Eli Lilly and Company (LLY)vsScynexis Inc (SCYX)
LLY
Eli Lilly and Company
$1,220.42
+0.43%
HEALTHCARE · Cap: $1.02T
SCYX
Scynexis Inc
$4.81
-0.52%
HEALTHCARE · Cap: $299.50M
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 355037% more annual revenue ($72.25B vs $20.34M). LLY leads profitability with a 35.0% profit margin vs -120.5%. LLY earns a higher WallStSmart Score of 76/100 (B+).
LLY
Strong Buy76
out of 100
Grade: B+
SCYX
Hold35
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 79 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 49.4%
Revenue surging 55.5% year-over-year
Earnings expanding 169.9% YoY
Reasonable price relative to book value
Revenue surging 1809.0% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Expensive relative to growth rate
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 34.9x book value
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -53.4% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.
Bull Case : SCYX
The strongest argument for SCYX centers on Price/Book, Revenue Growth, Debt/Equity. Revenue growth of 1809.0% demonstrates continued momentum.
Bear Case : LLY
The primary concerns for LLY are PEG Ratio, P/E Ratio, Debt/Equity. Debt-to-equity of 1.62 is elevated, increasing financial risk.
Bear Case : SCYX
The primary concerns for SCYX are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
LLY profiles as a growth stock while SCYX is a hypergrowth play — different risk/reward profiles.
SCYX carries more volatility with a beta of 1.10 — expect wider price swings.
SCYX is growing revenue faster at 1809.0% — sustainability is the question.
LLY generates stronger free cash flow (7.8B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (76/100 vs 35/100), backed by strong 35.0% margins and 55.5% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Scynexis Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
SCYNEXIS, Inc., a biotechnology company, offers therapies for the treatment of yeast infections in the United States. The company is headquartered in Jersey City, New Jersey.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?